Is SOLV or BLCO more profitable?

Solventum has a net margin of 17.33% compared to Bausch + Lomb's net margin of -4.21%. Solventum's return on equity of 23.51% beat Bausch + Lomb's return on equity. Company Net Margins Return on Equity Return on Assets Solventum 17.33% 23.51% 7.63% Bausch + Lomb -4.21% 3.60% 1.69%

Which has higher earnings & valuation, SNN or BLCO?

Smith & Nephew SNATS has higher revenue and earnings than Bausch + Lomb. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Smith & Nephew SNATS $6.16B 2.04 $625M N/A N/A Bausch + Lomb $5.10B 1.07 -$360M -$0.62 N/A

Is PEN or BLCO more profitable?

Penumbra has a net margin of 11.76% compared to Bausch + Lomb's net margin of -4.21%. Penumbra's return on equity of 10.87% beat Bausch + Lomb's return on equity. Company Net Margins Return on Equity Return on Assets Penumbra 11.76% 10.87% 8.45% Bausch + Lomb -4.21% 3.60% 1.69%

Which has preferable earnings & valuation, GKOS or BLCO?

Glaukos has higher earnings, but lower revenue than Bausch + Lomb. Glaukos is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 15.64 -$187.69M -$3.28 N/A Bausch + Lomb $5.10B 1.07 -$360M -$0.62 N/A

Is GKOS or BLCO more profitable?

Bausch + Lomb has a net margin of -4.21% compared to Glaukos' net margin of -34.34%. Bausch + Lomb's return on equity of 3.60% beat Glaukos' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -34.34% -6.92% -5.25% Bausch + Lomb -4.21% 3.60% 1.69%

Bausch + Lomb (BLCO) Competitors

$15.25 +0.32 (+2.14%)

Closing price 03:58 PM Eastern

Extended Trading

$15.10 -0.15 (-1.02%)

As of 06:49 PM Eastern

Compare

BLCO vs. ZBH, SOLV, SNN, PEN, and GKOS

Should you buy Bausch + Lomb stock or one of its competitors? MarketBeat compares Bausch + Lomb with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bausch + Lomb include Zimmer Biomet (ZBH), Solventum (SOLV), Smith & Nephew SNATS (SNN), Penumbra (PEN), and Glaukos (GKOS). These companies are all part of the "medical equipment" industry.

How does Bausch + Lomb compare to Zimmer Biomet?

Zimmer Biomet (NYSE:ZBH) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

In the previous week, Zimmer Biomet had 8 more articles in the media than Bausch + Lomb. MarketBeat recorded 8 mentions for Zimmer Biomet and 0 mentions for Bausch + Lomb. Zimmer Biomet's average media sentiment score of 1.19 beat Bausch + Lomb's score of 0.98 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Overall Sentiment
Zimmer Biomet	Positive
Bausch + Lomb	Positive

Zimmer Biomet presently has a consensus target price of $102.70, suggesting a potential upside of 17.18%. Bausch + Lomb has a consensus target price of $17.92, suggesting a potential upside of 17.49%. Given Bausch + Lomb's higher possible upside, analysts plainly believe Bausch + Lomb is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	3 Sell rating(s)	12 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.26
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Zimmer Biomet has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$8.41B	2.02	$705.20M	$3.85	22.76
Bausch + Lomb	$5.10B	1.07	-$360M	-$0.62	N/A

88.9% of Zimmer Biomet shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Zimmer Biomet has a net margin of 9.05% compared to Bausch + Lomb's net margin of -4.21%. Zimmer Biomet's return on equity of 13.24% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	9.05%	13.24%	7.28%
Bausch + Lomb	-4.21%	3.60%	1.69%

Zimmer Biomet has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

Summary

Zimmer Biomet beats Bausch + Lomb on 14 of the 17 factors compared between the two stocks.

How does Bausch + Lomb compare to Solventum?

Solventum (NYSE:SOLV) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Solventum has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solventum	$8.26B	1.55	$1.56B	$8.16	9.09
Bausch + Lomb	$5.10B	1.07	-$360M	-$0.62	N/A

In the previous week, Solventum had 3 more articles in the media than Bausch + Lomb. MarketBeat recorded 3 mentions for Solventum and 0 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 0.98 beat Solventum's score of 0.25 indicating that Bausch + Lomb is being referred to more favorably in the news media.

Company	Overall Sentiment
Solventum	Neutral
Bausch + Lomb	Positive

Solventum has a net margin of 17.33% compared to Bausch + Lomb's net margin of -4.21%. Solventum's return on equity of 23.51% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solventum	17.33%	23.51%	7.63%
Bausch + Lomb	-4.21%	3.60%	1.69%

Solventum has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market.

Solventum currently has a consensus price target of $84.25, suggesting a potential upside of 13.64%. Bausch + Lomb has a consensus price target of $17.92, suggesting a potential upside of 17.49%. Given Bausch + Lomb's higher probable upside, analysts clearly believe Bausch + Lomb is more favorable than Solventum.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solventum	1 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

11.1% of Bausch + Lomb shares are held by institutional investors. 0.2% of Solventum shares are held by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Solventum beats Bausch + Lomb on 12 of the 16 factors compared between the two stocks.

How does Bausch + Lomb compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Smith & Nephew SNATS has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.58, suggesting that its stock price is 42% less volatile than the broader market.

Smith & Nephew SNATS has higher revenue and earnings than Bausch + Lomb.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Smith & Nephew SNATS	$6.16B	2.04	$625M	N/A	N/A
Bausch + Lomb	$5.10B	1.07	-$360M	-$0.62	N/A

25.6% of Smith & Nephew SNATS shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Bausch + Lomb's average media sentiment score of 0.98 beat Smith & Nephew SNATS's score of 0.00 indicating that Bausch + Lomb is being referred to more favorably in the news media.

Company	Overall Sentiment
Smith & Nephew SNATS	Neutral
Bausch + Lomb	Positive

Smith & Nephew SNATS presently has a consensus target price of $30.93, suggesting a potential upside of 4.41%. Bausch + Lomb has a consensus target price of $17.92, suggesting a potential upside of 17.49%. Given Bausch + Lomb's stronger consensus rating and higher probable upside, analysts clearly believe Bausch + Lomb is more favorable than Smith & Nephew SNATS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Smith & Nephew SNATS	0 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.17
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Smith & Nephew SNATS has a net margin of 0.00% compared to Bausch + Lomb's net margin of -4.21%. Bausch + Lomb's return on equity of 3.60% beat Smith & Nephew SNATS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Smith & Nephew SNATS	N/A	N/A	N/A
Bausch + Lomb	-4.21%	3.60%	1.69%

Summary

Bausch + Lomb beats Smith & Nephew SNATS on 8 of the 13 factors compared between the two stocks.

How does Bausch + Lomb compare to Penumbra?

Penumbra (NYSE:PEN) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Penumbra has a net margin of 11.76% compared to Bausch + Lomb's net margin of -4.21%. Penumbra's return on equity of 10.87% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Penumbra	11.76%	10.87%	8.45%
Bausch + Lomb	-4.21%	3.60%	1.69%

Penumbra presently has a consensus price target of $361.33, suggesting a potential upside of 13.60%. Bausch + Lomb has a consensus price target of $17.92, suggesting a potential upside of 17.49%. Given Bausch + Lomb's stronger consensus rating and higher possible upside, analysts plainly believe Bausch + Lomb is more favorable than Penumbra.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

88.9% of Penumbra shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 2.9% of Penumbra shares are owned by company insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Penumbra has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Penumbra	$1.40B	8.91	$177.69M	$4.34	73.29
Bausch + Lomb	$5.10B	1.07	-$360M	-$0.62	N/A

In the previous week, Penumbra had 2 more articles in the media than Bausch + Lomb. MarketBeat recorded 2 mentions for Penumbra and 0 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 0.98 beat Penumbra's score of 0.68 indicating that Bausch + Lomb is being referred to more favorably in the news media.

Company	Overall Sentiment
Penumbra	Positive
Bausch + Lomb	Positive

Penumbra has a beta of 0.71, meaning that its share price is 29% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

Summary

Penumbra beats Bausch + Lomb on 11 of the 16 factors compared between the two stocks.

How does Bausch + Lomb compare to Glaukos?

Glaukos (NYSE:GKOS) and Bausch + Lomb (NYSE:BLCO) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

Glaukos currently has a consensus target price of $149.17, suggesting a potential upside of 10.42%. Bausch + Lomb has a consensus target price of $17.92, suggesting a potential upside of 17.49%. Given Bausch + Lomb's higher possible upside, analysts plainly believe Bausch + Lomb is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Bausch + Lomb has a net margin of -4.21% compared to Glaukos' net margin of -34.34%. Bausch + Lomb's return on equity of 3.60% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Bausch + Lomb	-4.21%	3.60%	1.69%

99.0% of Glaukos shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 5.9% of Glaukos shares are owned by insiders. Comparatively, 1.5% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Glaukos had 6 more articles in the media than Bausch + Lomb. MarketBeat recorded 6 mentions for Glaukos and 0 mentions for Bausch + Lomb. Glaukos' average media sentiment score of 0.99 beat Bausch + Lomb's score of 0.98 indicating that Glaukos is being referred to more favorably in the media.

Company	Overall Sentiment
Glaukos	Positive
Bausch + Lomb	Positive

Glaukos has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

Glaukos has higher earnings, but lower revenue than Bausch + Lomb. Glaukos is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	15.64	-$187.69M	-$3.28	N/A
Bausch + Lomb	$5.10B	1.07	-$360M	-$0.62	N/A

Summary

Glaukos beats Bausch + Lomb on 9 of the 16 factors compared between the two stocks.

Get Bausch + Lomb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLCO vs. The Competition

Export

Metric	Bausch + Lomb	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$5.44B	$8.67B	$6.47B	$23.14B
Dividend Yield	N/A	1.73%	2.68%	4.06%
P/E Ratio	-24.60	23.42	24.71	31.08
Price / Sales	1.07	16.78	491.85	108.37
Price / Cash	8.91	13.96	27.92	18.65
Price / Book	0.83	6.21	10.82	4.65
Net Income	-$360M	$174.80M	$3.56B	$1.07B
7 Day Performance	1.78%	2.03%	1.67%	-1.04%
1 Month Performance	-4.39%	1.54%	0.43%	0.18%
1 Year Performance	27.03%	10.30%	32.84%	24.25%

Bausch + Lomb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLCO Bausch + Lomb	3.5449 of 5 stars	$15.25 +2.1%	$17.92 +17.5%	+27.4%	$5.44B	$5.10B	N/A	13,000
ZBH Zimmer Biomet	4.7332 of 5 stars	$88.54 +1.6%	$102.70 +16.0%	-4.3%	$17.13B	$8.41B	23.00	17,000	Positive News
SOLV Solventum	3.4907 of 5 stars	$78.85 -0.5%	$84.25 +6.8%	-0.1%	$13.66B	$8.26B	9.66	20,000
SNN Smith & Nephew SNATS	2.0944 of 5 stars	$30.52 -0.5%	$30.93 +1.3%	+2.0%	$13.00B	$6.16B	N/A	16,988
PEN Penumbra	2.5313 of 5 stars	$318.63 +0.1%	$361.33 +13.4%	+23.3%	$12.54B	$1.40B	73.42	4,700

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BLCO) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bausch + Lomb (BLCO) Competitors

BLCO vs. ZBH, SOLV, SNN, PEN, and GKOS

How does Bausch + Lomb compare to Zimmer Biomet?

Summary

How does Bausch + Lomb compare to Solventum?

Summary

How does Bausch + Lomb compare to Smith & Nephew SNATS?

Summary

How does Bausch + Lomb compare to Penumbra?

Summary

How does Bausch + Lomb compare to Glaukos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLCO vs. The Competition

Bausch + Lomb Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bausch + Lomb (BLCO) Competitors

BLCO vs. ZBH, SOLV, SNN, PEN, and GKOS

How does Bausch + Lomb compare to Zimmer Biomet?

Does the media refer more to ZBH or BLCO?

Do analysts rate ZBH or BLCO?

Which has stronger earnings and valuation, ZBH or BLCO?

Do institutionals and insiders hold more shares of ZBH or BLCO?

Is ZBH or BLCO more profitable?

Which has more risk and volatility, ZBH or BLCO?

Summary

How does Bausch + Lomb compare to Solventum?

Which has better valuation and earnings, SOLV or BLCO?

Does the media refer more to SOLV or BLCO?

Is SOLV or BLCO more profitable?

Which has more risk & volatility, SOLV or BLCO?

Do analysts recommend SOLV or BLCO?

Do institutionals & insiders hold more shares of SOLV or BLCO?

Summary

How does Bausch + Lomb compare to Smith & Nephew SNATS?

Which has more volatility & risk, SNN or BLCO?

Which has higher earnings & valuation, SNN or BLCO?

Do insiders & institutionals hold more shares of SNN or BLCO?

Does the media prefer SNN or BLCO?

Do analysts recommend SNN or BLCO?

Is SNN or BLCO more profitable?

Summary

How does Bausch + Lomb compare to Penumbra?

Is PEN or BLCO more profitable?

Do analysts prefer PEN or BLCO?

Do insiders and institutionals hold more shares of PEN or BLCO?

Which has higher valuation and earnings, PEN or BLCO?

Does the media refer more to PEN or BLCO?

Which has more volatility & risk, PEN or BLCO?

Summary

How does Bausch + Lomb compare to Glaukos?

Do analysts rate GKOS or BLCO?

Is GKOS or BLCO more profitable?

Do insiders & institutionals hold more shares of GKOS or BLCO?

Does the media refer more to GKOS or BLCO?

Which has more risk and volatility, GKOS or BLCO?

Which has preferable earnings & valuation, GKOS or BLCO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLCO vs. The Competition

Bausch + Lomb Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools